Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
复制标题
DOI：
10.1093/annonc/mdp508
复制
发表时间：
2010-04-01
影响因子：
50.5
通讯作者：
Baccarani, M.
中科院分区：
文献类型：
--
作者：
Zinzani, P. L.;Venturini, F.;Baccarani, M.
背景：未明确的外周t细胞淋巴瘤（PTCLU）和蕈样真菌病（MF）经常表现出对常规化疗的耐药性。吉西他滨应该被认为是一个合适的选择。我们报告了39例接受吉西他滨治疗的t细胞淋巴瘤患者的长期更新。患者和方法：1997年5月至2007年9月，39例MF和PTCLU患者接受吉西他滨治疗。纳入标准为：组织学诊断为MF或PTCLU；复发/难治性疾病;年龄>= 18岁；和世界卫生组织业绩状态二项或以下。MF 19例，PTCLU 20例。所有MF患者均为T3-T4、N0和M0期疾病，PTCLU患者为III-IV期疾病。吉西他滨在第1、8和15天给予，疗程为28天（1200mg /m(2)/天），总共3至6个周期。结果：总有效率为51%（39例患者中有20例）；完全缓解（CR）和部分缓解（PR）率分别为23%（39例患者中9例）和28%（39例患者中11例）。MF患者的CR率为16%，PR率为32%，PTCLU患者的CR率为30%，PR率为25%。在CR患者中，9例中有7例持续完全缓解，无病间隔（15-120个月）不等。结论：根据我们的经验，吉西他滨被证明对预处理MF和PTCLU患者是有效的，即使是长期的。
Background: Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy. Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine.Patients and methods: From May 1997 to September 2007, 39 pretreated MF and PTCLU patients received gemcitabine. Inclusion criteria were as follows: histologic diagnosis of MF or PTCLU; relapsed/refractory disease; age >= 18 years; and World Health Organization performance status of two or less. Nineteen patients had MF and 20 PTCLU. All patients with MF had a T3-T4, N0, and M0 disease and patients with PTCLU had stage III-IV disease. Gemcitabine was given on days 1, 8, and 15 on a 28-day schedule (1200 mg/m(2)/day) for a total of three to six cycles.Results: Overall response rate was 51% (20 of 39 patients); complete response (CR) and partial response (PR) rates were 23% (9 of 39 patients) and 28% (11 of 39 patients), respectively. Patients with MF had a CR rate of 16% and a PR rate of 32% compared with a CR rate of 30% and a PR rate of 25% of PTCLU patients. Among the CR patients, 7 of 9 are in continuous complete response with a variable disease-free interval (15-120 months).Conclusion: In our experience, gemcitabine proved to be effective in pretreated MF and PTCLU patients, even in the long term.